Chemistry:Rovafovir etalafenamide

From HandWiki
Revision as of 03:58, 6 February 2024 by LinuxGuru (talk | contribs) (url)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Rovafovir etalafenamide
Rovafovir etalafenamide.svg
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H24FN6O6P
Molar mass506.431 g·mol−1
3D model (JSmol)

Rovafovir etalafenamide (development code GS-9131) is an experimental drug for the treatment of HIV-1 infection.[1] Rovafovir etalafenamide is a nucleotide reverse transcriptase inhibitor and prodrug of GS-9148. Rovafovir etalafenamide itself has no antiviral activity, but once consumed it is metabolized through the hydrolysis of the phosphonoamidate group to generate the antiviral compound GS-9148.[1]

Chemical strucuture of GS-9148, the active antiviral agent

The drug is being developed by Gilead Sciences.[2]

Rovafovir etalafenamide shows antiviral activity against viruses containing major mutations associated with resistance to the nucleoside analog reverse-transcriptase inhibitors which are commonly used to treat HIV/AIDS infection.[1]

The methods by which the drug is synthesized by been published.[3][4][5]

References

  1. 1.0 1.1 1.2 "Rovafovir etalafenamide. Nucleotide reverse transcriptase inhibitor, Treatment of HIV-1 infection". Drugs of the Future 45 (7): 459. 2020. doi:10.1358/DOF.2020.45.7.3123468. 
  2. "Rovafovir etalafenamide - Gilead Sciences". Adis Insight. https://adisinsight.springer.com/drugs/800016343. 
  3. "Synthesis of Rovafovir Etalafenamide (Part I): Active Pharmaceutical Ingredient Process Development, Scale-Up, and Impurity Control Strategy". Organic Process Research & Development 25 (5): 1215–1236. 2021. doi:10.1021/acs.oprd.1c00059. 
  4. "Synthesis of Rovafovir Etalafenamide (Part II): Dynamic Control for Successful Scale-Up of an Oxygen-Releasing Elimination Reaction Mediated by Oxone". Organic Process Research & Development 25 (5): 1237–1246. 2021. doi:10.1021/acs.oprd.0c00439. 
  5. "Synthesis of Rovafovir Etalafenamide (Part III): Evolution of the Synthetic Process to the Phosphonamidate Fragment". Organic Process Research & Development 25 (5): 1247–1262. 2021. doi:10.1021/acs.oprd.0c00428.